Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 12, 2016 18:56:33 GMT -5
Did the 35% retention rate put out by Sanofi include patients who used samples and then discontinued use due to being denied by their insurance or because of the cost? That's an easy answer ask Sanofi
|
|
|
Post by bioexec25 on Jan 12, 2016 19:07:47 GMT -5
Did the 35% retention rate put out by Sanofi include patients who used samples and then discontinued use due to being denied by their insurance or because of the cost? I don't trust the number. But let's use their number for debate, it is no surprise based on many things, e.g. FDA labeling dosing, cost, luke warm docs, ins, etc etc. In summary, it is an arbitrary and capricious statement. A seemingly good idea, brutally murdered by a gang of facts.
|
|
|
Post by beardawg on Jan 12, 2016 19:15:25 GMT -5
Did the 35% retention rate put out by Sanofi include patients who used samples and then discontinued use due to being denied by their insurance or because of the cost? That's an easy answer ask Sanofi Of course they won't answer that, because then the onus is back on them because we know it wasn't the product. Their statement implied it was the product. Sanofi wants to make it seem like the product failed instead of them failing. It's like a race car driver being given the fastest car, then running the whole time in 2nd gear, only to complain that the car wasn't fast enough to win the race. It's like if Burger King came out with a McRib competitor that was actually rib meat, but priced it at $125, then complained of slow sales.
|
|
|
Post by u1682002 on Jan 12, 2016 19:58:30 GMT -5
Nothing will not quiet down the doubters except the following two things:
1. Al DECIDED to increase the LOC by a significant amount or an agreement has already been signed with a new partner with a significant up front payment.
2. Matt to buy a significant number of shares now from open market using his own money.
Powerpoint plans are very easy to be generated and I have read too many of them over the years. They mean nothing!
So I would argue that we should all focus on whether or not Matt will buy shares from open market if he show empty-handed with item#1. If you are planning to attend this call and submitting questions, you should add the #2 to your first questions. We can at least keep him honest. I will send my 3 questions to Matt tonight with a title of "Questions to be asked tomorrow". If there are a few of us do the same, I think there is a good chance to got Matt's attention since it is MNKD decision to open this QA session to all and he would like to get a idea what kind of questions he will face tomorrow.
|
|
|
Post by peppy on Jan 13, 2016 5:24:02 GMT -5
I think 3 is THE QUESTION that NEEDS to be asked - but perhaps in a more nuanced way or with more specific follow ups. 1. Did Mannkind ever execute their technology transfer obligation to Sanofi? 2. Did Sanofi at anytime before September 3rd, ever explain anything or offer any information on or about their plans to expand their Wilshire UK INHALABLES PLANT? If so was it consistent with their statement - a response to growing consumer demand(their/sny's words) for their PRODUCTS and CMO business? If not, what message did you perceive they were sending in light of a publiscized report citing consumer demand for their inhalable products as the key driver of this site expansion? 3. Was Sanofi involved in any capacity in the decision to increase production at the Danbury plant in late April? 4. Did Sanofi, according to the stipulations supply agreement, obligate themselves accordingly or at all - with particular respect to timing and procedure? If not, how would you characterize their level of communication? I would rather ask future plans.. Sekc4u; What questions would you ask?
|
|
|
Post by mnholdem on Jan 13, 2016 8:06:02 GMT -5
I agree with @iam2sekc4u2002 about asking CEO Pfeffer to explain MannKind's future plans. Unless I'm mistaken, Matt cannot yet disclose Sanofi's commercialization plan for Afrezza because the non-disclosure provisions remains until the effective termination date, which appears to be April 3, 2016.
However, Matt certainly can and should state that the company plans to remove the premium price placed on Afrezza in order for it be competitively priced with RAA insulin. Only we need to be prepared for the likelihood that, because of the Sanofi NDA provisions currently in effect, Matt may not be able to talk about whether management has had disagreements with Sanofi's pricing policy or payer reimbursement efforts or even talk about how Sanofi erred with its U.S. commercialization strategy for Afrezza.
|
|
|
Post by fofos2000i on Jan 13, 2016 8:21:29 GMT -5
i would like to obtain some feedback on how does the transition plays out . Any obligations that need to be carried out bby Sanofi ?
|
|
|
Post by mnkdmorelong on Jan 13, 2016 8:29:28 GMT -5
I agree with @iam2sekc4u2002 about asking CEO Pfeffer to explain MannKind's future plans. Unless I'm mistaken, Matt cannot yet disclose Sanofi's commercialization plan for Afrezza because the non-disclosure provisions remains until the effective termination date, which appears to be April 3, 2016.
However, Matt certainly can and should state that the company plans to remove the premium price placed on Afrezza in order for it be competitively priced with RAA insulin. Only we need to be prepared for the likelihood that, because of the Sanofi NDA provisions currently in effect, Matt may not be able to talk about whether management has had disagreements with Sanofi's pricing policy or payer reimbursement efforts or even talk about how Sanofi erred with its U.S. commercialization strategy for Afrezza. The 2X+ pricing of Afrezza vs. other RAAs is a huge impediment. I would ask Matt if competitive pricing of Afrezza necessitates a go alone strategy. This means that there is not enough in the gross margin apple for two people to take a bite.
|
|
|
Post by u1682002 on Jan 13, 2016 9:06:17 GMT -5
My guess is that most of the questions raised here (if not all) will be raised by the analysts if time permits. I think they will get the first priority to raise their questions. Once it open to individual investor (if it is indeed like what lakers stated in his post), then we should focus on questioning the new CEO's commitment (I doubt analysts will question this) if there is no news announcement about any specific additional cash inflow during the conference call. It may sound like a little bit rude to do so, but we small individual investors have simply got too many brutal awakening calls over these years. Most of them may be out of the management control but some of them are management decision related.
|
|
|
Post by mnholdem on Jan 13, 2016 9:10:42 GMT -5
That would be an excellent question: "Matt, does Afrezza have a low enough cost to be able to be competitively priced against injected RAA insulin and maintain an acceptable profit margin?"
|
|
|
Post by suebeeee1 on Jan 13, 2016 9:16:02 GMT -5
I agree with @iam2sekc4u2002 about asking CEO Pfeffer to explain MannKind's future plans. Unless I'm mistaken, Matt cannot yet disclose Sanofi's commercialization plan for Afrezza because the non-disclosure provisions remains until the effective termination date, which appears to be April 3, 2016.
However, Matt certainly can and should state that the company plans to remove the premium price placed on Afrezza in order for it be competitively priced with RAA insulin. Only we need to be prepared for the likelihood that, because of the Sanofi NDA provisions currently in effect, Matt may not be able to talk about whether management has had disagreements with Sanofi's pricing policy or payer reimbursement efforts or even talk about how Sanofi erred with its U.S. commercialization strategy for Afrezza. AND...if MNKD takes a payoff from SNY to end partnership without suing them, they may never be able to give any details about what happened. They may never be able to utter one bad word about their "partner". Thats ok with me if they get enough money out of it to continue.
|
|
|
Post by u1682002 on Jan 13, 2016 9:22:40 GMT -5
MN, this is an excellent question that I like to know the answer most. I will dial in today and I will put your question as my top question list. The question to you is how we can search this kind of answer if the question is not got answered during this call. Al commented about the pricing of Afrezza before and he said it would be competitive to the injected version. If MNKD to cut the retail price by 50% like many suggested, do you think it will have any profit margin left for MNKD?
|
|
|
Post by mnholdem on Jan 13, 2016 9:35:21 GMT -5
Actually, I think that I know the answer anyway, but I'd still like Matt to put the answer out there regarding competitive pricing. It was Matt, himself, who let slip over a year ago that the Sanofi 65/35 split was the equivalent of a mid-20% royalties deal. Anyone who knows how to reverse-engineer the numbers can use that comment of Matt's to calculate that Afrezza is manufactured at about 85%-90% profit margin.
|
|
|
Post by mnkdmorelong on Jan 13, 2016 9:37:05 GMT -5
MN, this is an excellent question that I like to know the answer most. I will dial in today and I will put your question as my top question list. The question to you is how we can search this kind of answer if the question is not got answered during this call. Al commented about the pricing of Afrezza before and he said it would be competitive to the injected version. If MNKD to cut the retail price by 50% like many suggested, do you think it will have any profit margin left for MNKD? The way you phrased the question will put pressure on Matt. A better phraseology is: If MNKD cuts the retail price by 50% like many suggested, will the smaller gross margin change MNKD's go to market strategy. Meaning, do you have reduce channel costs by not having a partner?
|
|
|
Post by suebeeee1 on Jan 13, 2016 9:46:32 GMT -5
All I want is for Matt, in his general presentation, to present a clear path foward. I have no idea why MNKD would be presenting at this conference if they have nothing to say. I want the presentors to answer these questions without having to be asked.
If you go forward alone, where is the cash going to come from to survive? Is there a pipeline and what work is being done on it. If you partner, what are the terms of the deal, no secrets anymore. You owe shareholders that. If you are preparing either Afrezza or the whole company for sale, at least let us know. If you think we can't get through and BNK is our only option, at least tell us you are talking to lawyers about "options".
|
|